But the issue with CRISPR is that it's been a slow rollout, and its business continues to incur significant losses. Is it ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...

The past few years have been challenging for the biotech.

The company could finally be ready to deliver on years of promise.

CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...

CRISPR Therapeutics AG CRSP shares jumped on Thursday, building on its Feb. 13 earnings report that showed growing momentum for its lead gene therapy and a deepening pipeline. Casgevy Revenue Casgevy, ...

CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...

Shares of gene therapy specialist, CRISPR Therapeutics (NASDAQ: CRSP) have been beaten down a long way despite some impressive accomplishments. The company already earned approval to sell its first ...

CRISPR Therapeutics had its first FDA-approved product in December 2023, a treatment for sickle cell disease called Casgevy. It’s also developing treatments for cancer and cardiovascular disease using ...